FI68232C - Foerfarande foer framstaellning av benzotiazolinfoereningar me farmaceutiskt verkan - Google Patents
Foerfarande foer framstaellning av benzotiazolinfoereningar me farmaceutiskt verkan Download PDFInfo
- Publication number
- FI68232C FI68232C FI831431A FI831431A FI68232C FI 68232 C FI68232 C FI 68232C FI 831431 A FI831431 A FI 831431A FI 831431 A FI831431 A FI 831431A FI 68232 C FI68232 C FI 68232C
- Authority
- FI
- Finland
- Prior art keywords
- iii
- csj
- formula
- cnj
- compound
- Prior art date
Links
- 238000012423 maintenance Methods 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 24
- 125000001589 carboacyl group Chemical group 0.000 claims abstract description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 13
- 239000001257 hydrogen Substances 0.000 claims abstract description 13
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 13
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims abstract description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 12
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 11
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 11
- 150000002367 halogens Chemical class 0.000 claims abstract description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 11
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 4
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 70
- 238000000034 method Methods 0.000 claims description 22
- 150000001412 amines Chemical class 0.000 claims description 18
- -1 hydroxy, phenyl Chemical group 0.000 claims description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 4
- 239000004593 Epoxy Substances 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 125000005936 piperidyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000004526 pharmaceutical effect Effects 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 41
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 101100515517 Arabidopsis thaliana XI-I gene Proteins 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000011575 calcium Substances 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 239000001913 cellulose Substances 0.000 description 7
- 229920002678 cellulose Polymers 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 230000002744 anti-aggregatory effect Effects 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- WOHLSTOWRAOMSG-UHFFFAOYSA-N 2,3-dihydro-1,3-benzothiazole Chemical compound C1=CC=C2SCNC2=C1 WOHLSTOWRAOMSG-UHFFFAOYSA-N 0.000 description 3
- XBHOUXSGHYZCNH-UHFFFAOYSA-N 2-phenyl-1,3-benzothiazole Chemical class C1=CC=CC=C1C1=NC2=CC=CC=C2S1 XBHOUXSGHYZCNH-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 230000002213 calciumantagonistic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000001033 ether group Chemical group 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000004623 platelet-rich plasma Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- SBGBDJWLVSPTLA-UHFFFAOYSA-N 1-[2-(2-hydroxyphenyl)-2h-1,3-benzothiazol-3-yl]ethanone Chemical compound S1C2=CC=CC=C2N(C(=O)C)C1C1=CC=CC=C1O SBGBDJWLVSPTLA-UHFFFAOYSA-N 0.000 description 2
- GPVSWJHHWDHNFD-UHFFFAOYSA-N 1-[2-[2-(3-chloropropoxy)phenyl]-2h-1,3-benzothiazol-3-yl]ethanone Chemical compound S1C2=CC=CC=C2N(C(=O)C)C1C1=CC=CC=C1OCCCCl GPVSWJHHWDHNFD-UHFFFAOYSA-N 0.000 description 2
- AEZDTSGMPDCBEL-UHFFFAOYSA-N 1-[2-[2-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-2h-1,3-benzothiazol-3-yl]ethanone;hydrochloride Chemical compound Cl.S1C2=CC=CC=C2N(C(=O)C)C1C1=CC=CC=C1OCC(O)CNC(C)(C)C AEZDTSGMPDCBEL-UHFFFAOYSA-N 0.000 description 2
- NYYRRBOMNHUCLB-UHFFFAOYSA-N 3-chloro-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCCl NYYRRBOMNHUCLB-UHFFFAOYSA-N 0.000 description 2
- SXJNOUNWIUGTEN-UHFFFAOYSA-N 4-[2-(3-acetyl-2h-1,3-benzothiazol-2-yl)phenoxy]butanoic acid Chemical compound S1C2=CC=CC=C2N(C(=O)C)C1C1=CC=CC=C1OCCCC(O)=O SXJNOUNWIUGTEN-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 241000764238 Isis Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- GFRROZIJVHUSKZ-FXGMSQOLSA-N OS I Natural products C[C@@H]1O[C@@H](O[C@H]2[C@@H](O)[C@@H](CO)O[C@@H](OC[C@@H](O)[C@@H](O)[C@@H](O)CO)[C@@H]2NC(=O)C)[C@H](O)[C@H](O)[C@H]1O GFRROZIJVHUSKZ-FXGMSQOLSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 101000870345 Vasconcellea cundinamarcensis Cysteine proteinase 1 Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000006502 antiplatelets effects Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000002440 hydroxy compounds Chemical class 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- PSBUHSGPDBSLFR-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-[2-[2-[3-(methylamino)propoxy]phenyl]-2h-1,3-benzothiazol-3-yl]ethanone Chemical compound OC(=O)\C=C\C(O)=O.CNCCCOC1=CC=CC=C1C1N(C(C)=O)C2=CC=CC=C2S1 PSBUHSGPDBSLFR-WLHGVMLRSA-N 0.000 description 1
- UDLBCTPWBIWVND-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-[2-[3-[3-[cyclohexyl(methyl)amino]propoxy]-4-hydroxyphenyl]-2h-1,3-benzothiazol-3-yl]ethanone Chemical compound OC(=O)\C=C\C(O)=O.C=1C(C2N(C3=CC=CC=C3S2)C(C)=O)=CC=C(O)C=1OCCCN(C)C1CCCCC1 UDLBCTPWBIWVND-WLHGVMLRSA-N 0.000 description 1
- VNQCPVKUMSFXFN-UHFFFAOYSA-N 1-[2-(3,4-dimethoxyphenyl)ethyl]piperazine Chemical compound C1=C(OC)C(OC)=CC=C1CCN1CCNCC1 VNQCPVKUMSFXFN-UHFFFAOYSA-N 0.000 description 1
- JNPNQBUXJFXPKA-UHFFFAOYSA-N 1-[2-[2-(3-aminopropoxy)phenyl]-2h-1,3-benzothiazol-3-yl]ethanone;hydrochloride Chemical compound Cl.S1C2=CC=CC=C2N(C(=O)C)C1C1=CC=CC=C1OCCCN JNPNQBUXJFXPKA-UHFFFAOYSA-N 0.000 description 1
- XBVFWLFAIJXSEY-UHFFFAOYSA-N 1-[2-[2-(3-chloro-2-hydroxypropoxy)phenyl]-2h-1,3-benzothiazol-3-yl]ethanone Chemical compound S1C2=CC=CC=C2N(C(=O)C)C1C1=CC=CC=C1OCC(O)CCl XBVFWLFAIJXSEY-UHFFFAOYSA-N 0.000 description 1
- AKDUORQJINOLHT-UHFFFAOYSA-N 1-[2-[2-(5-bromopentoxy)-5-methoxyphenyl]-2h-1,3-benzothiazol-3-yl]ethanone Chemical compound COC1=CC=C(OCCCCCBr)C(C2N(C3=CC=CC=C3S2)C(C)=O)=C1 AKDUORQJINOLHT-UHFFFAOYSA-N 0.000 description 1
- MTLWWEQIGTXCIM-UHFFFAOYSA-N 1-[2-[2-[3-(diethylamino)propoxy]phenyl]-2h-1,3-benzothiazol-3-yl]ethanone;hydrochloride Chemical compound Cl.CCN(CC)CCCOC1=CC=CC=C1C1N(C(C)=O)C2=CC=CC=C2S1 MTLWWEQIGTXCIM-UHFFFAOYSA-N 0.000 description 1
- GAANQPCIQBLSAH-UHFFFAOYSA-N 1-[2-[2-[3-(dimethylamino)propoxy]phenyl]-2h-1,3-benzothiazol-3-yl]ethanone Chemical compound CN(C)CCCOC1=CC=CC=C1C1N(C(C)=O)C2=CC=CC=C2S1 GAANQPCIQBLSAH-UHFFFAOYSA-N 0.000 description 1
- BVXUXNQFBYNYFN-UHFFFAOYSA-N 1-[2-[3-(3-chloropropoxy)-4-hydroxyphenyl]-2h-1,3-benzothiazol-3-yl]ethanone Chemical compound S1C2=CC=CC=C2N(C(=O)C)C1C1=CC=C(O)C(OCCCCl)=C1 BVXUXNQFBYNYFN-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- HJFGULDHUDIPDA-UHFFFAOYSA-N 2-(2-formylphenyl)benzaldehyde Chemical compound O=CC1=CC=CC=C1C1=CC=CC=C1C=O HJFGULDHUDIPDA-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- CGFOXUUCJRQAJQ-UHFFFAOYSA-N 3-[2-(3-acetyl-2h-1,3-benzothiazol-2-yl)phenoxy]propanal Chemical compound S1C2=CC=CC=C2N(C(=O)C)C1C1=CC=CC=C1OCCC=O CGFOXUUCJRQAJQ-UHFFFAOYSA-N 0.000 description 1
- ZTGQZSKPSJUEBU-UHFFFAOYSA-N 3-bromopropan-1-amine Chemical compound NCCCBr ZTGQZSKPSJUEBU-UHFFFAOYSA-N 0.000 description 1
- JUIAPZCDFGNVFW-UHFFFAOYSA-N 4-[2-(3-acetyl-2h-1,3-benzothiazol-2-yl)phenoxy]-1-morpholin-4-ylbutan-1-one Chemical compound S1C2=CC=CC=C2N(C(=O)C)C1C1=CC=CC=C1OCCCC(=O)N1CCOCC1 JUIAPZCDFGNVFW-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- JGRPKOGHYBAVMW-UHFFFAOYSA-N 8-hydroxy-5-quinolinecarboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=C(O)C2=N1 JGRPKOGHYBAVMW-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 101001005269 Arabidopsis thaliana Ceramide synthase 1 LOH3 Proteins 0.000 description 1
- 101001005312 Arabidopsis thaliana Ceramide synthase LOH1 Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- MTWGXIFPZZZVAU-UHFFFAOYSA-N C(C)NCC.CNC1CCCCC1 Chemical compound C(C)NCC.CNC1CCCCC1 MTWGXIFPZZZVAU-UHFFFAOYSA-N 0.000 description 1
- SNHLLRYXXCVNRQ-SPIKMXEPSA-N C(\C=C/C(=O)O)(=O)O.C(\C=C/C(=O)O)(=O)O.C(C)(=O)N1C(SC2=C1C=CC=C2)C2=C(C=CC=C2)OCCN2C(CNCC2)CCC2=CC(=C(C=C2)OC)OC Chemical compound C(\C=C/C(=O)O)(=O)O.C(\C=C/C(=O)O)(=O)O.C(C)(=O)N1C(SC2=C1C=CC=C2)C2=C(C=CC=C2)OCCN2C(CNCC2)CCC2=CC(=C(C=C2)OC)OC SNHLLRYXXCVNRQ-SPIKMXEPSA-N 0.000 description 1
- OOGFDJXIMSAASI-WLHGVMLRSA-N C(\C=C\C(=O)O)(=O)O.C(C)(=O)N1C(SC2=C1C=CC=C2)C2=C(C=CC(=C2)OC)OCCCCCN(C)C2CCCCC2 Chemical compound C(\C=C\C(=O)O)(=O)O.C(C)(=O)N1C(SC2=C1C=CC=C2)C2=C(C=CC(=C2)OC)OCCCCCN(C)C2CCCCC2 OOGFDJXIMSAASI-WLHGVMLRSA-N 0.000 description 1
- 101100087530 Caenorhabditis elegans rom-1 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 101001089091 Cytisus scoparius 2-acetamido-2-deoxy-D-galactose-binding seed lectin 2 Proteins 0.000 description 1
- 101100536438 Escherichia coli (strain K12) tauB gene Proteins 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 101100346764 Mus musculus Mtln gene Proteins 0.000 description 1
- 101100305983 Mus musculus Rom1 gene Proteins 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- XTUVJUMINZSXGF-UHFFFAOYSA-N N-methylcyclohexylamine Chemical compound CNC1CCCCC1 XTUVJUMINZSXGF-UHFFFAOYSA-N 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N N-methylcyclohexylamine Natural products CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- 101001113857 Naja kaouthia Acidic phospholipase A2 2 Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical class OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- REJXASMKRGEMLD-UHFFFAOYSA-N ethyl 4-[2-(3-acetyl-2h-1,3-benzothiazol-2-yl)phenoxy]butanoate Chemical compound CCOC(=O)CCCOC1=CC=CC=C1C1N(C(C)=O)C2=CC=CC=C2S1 REJXASMKRGEMLD-UHFFFAOYSA-N 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000012739 integrated shape imaging system Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002689 maleic acids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- KFOPKOFKGJJEBW-ZSSYTAEJSA-N methyl 2-[(1s,7r,8s,9s,10r,13r,14s,17r)-1,7-dihydroxy-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]acetate Chemical compound C([C@H]1O)C2=CC(=O)C[C@H](O)[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](CC(=O)OC)[C@@]1(C)CC2 KFOPKOFKGJJEBW-ZSSYTAEJSA-N 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- DSNYFFJTZPIKFZ-UHFFFAOYSA-N propoxybenzene Chemical group CCCOC1=CC=CC=C1 DSNYFFJTZPIKFZ-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP56144148A JPS5846079A (ja) | 1981-09-12 | 1981-09-12 | ベンゾチアゾリン環を有するエ−テル類 |
JP14414881 | 1981-09-12 | ||
PCT/JP1982/000363 WO1983000865A1 (fr) | 1981-09-12 | 1982-09-10 | Composes de benzothiazoline |
JP8200363 | 1982-09-10 |
Publications (4)
Publication Number | Publication Date |
---|---|
FI831431L FI831431L (fi) | 1983-04-27 |
FI831431A0 FI831431A0 (fi) | 1983-04-27 |
FI68232B FI68232B (fi) | 1985-04-30 |
FI68232C true FI68232C (fi) | 1985-08-12 |
Family
ID=15355326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI831431A FI68232C (fi) | 1981-09-12 | 1983-04-27 | Foerfarande foer framstaellning av benzotiazolinfoereningar me farmaceutiskt verkan |
Country Status (18)
Country | Link |
---|---|
US (3) | US4479949A (fr) |
JP (1) | JPS5846079A (fr) |
AT (1) | AT379592B (fr) |
AU (1) | AU541223B2 (fr) |
BE (1) | BE894358A (fr) |
CA (1) | CA1169860A (fr) |
CH (1) | CH654001A5 (fr) |
DE (1) | DE3248957T1 (fr) |
DK (1) | DK164403C (fr) |
ES (2) | ES8308552A1 (fr) |
FI (1) | FI68232C (fr) |
FR (1) | FR2512820B1 (fr) |
GB (1) | GB2115815B (fr) |
IT (1) | IT1196423B (fr) |
NL (1) | NL8220310A (fr) |
NO (1) | NO831653L (fr) |
SE (1) | SE444681B (fr) |
WO (1) | WO1983000865A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56164877A (en) * | 1980-05-23 | 1981-12-18 | Fujitsu Ltd | Manufacture of head for thermal printer |
JPS5846079A (ja) * | 1981-09-12 | 1983-03-17 | Santen Pharmaceut Co Ltd | ベンゾチアゾリン環を有するエ−テル類 |
DK143684A (da) * | 1983-03-12 | 1984-09-13 | Bayer Ag | Anvendelse af pyrazolonderivater som lipoxygenasehaemmer ved terapi af isaer ischaemi og hjerterytmeforstyrrelser |
JPS60139679A (ja) * | 1983-12-27 | 1985-07-24 | Santen Pharmaceut Co Ltd | 2−アリ−ルベンゾチアゾリン誘導体 |
JPS60207396A (ja) * | 1984-03-31 | 1985-10-18 | ロ−ム株式会社 | 配線基板 |
JPS61110568A (ja) * | 1984-10-31 | 1986-05-28 | アルカテル・エヌ・ブイ | プリンタ装置 |
US4728651A (en) * | 1985-10-24 | 1988-03-01 | Hoechst-Roussel Pharmaceuticals Inc. | Antihypertensive thieno-isoxazoles and -pyrazoles |
JPS62221679A (ja) * | 1986-03-19 | 1987-09-29 | Santen Pharmaceut Co Ltd | ベンゾチアゾリン誘導体 |
US5147881A (en) * | 1990-11-14 | 1992-09-15 | Pfizer Inc | 4-(1,2-benzisoxazolyl)piperidine antipsychotic agents |
US5541204A (en) * | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
EP2042173A3 (fr) | 2002-03-29 | 2010-02-24 | Santen Pharmaceutical Co., Ltd. | Agoniste du récepteur kappa-opioide comprenant un dérivé de 2-phénylbenzothiazoline |
WO2014148574A1 (fr) * | 2013-03-22 | 2014-09-25 | 参天製薬株式会社 | Inhibition de la production d'il-2 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2996512A (en) * | 1961-08-15 | Therapeutic derivatives of aryl- | ||
US3117124A (en) * | 1957-03-20 | 1964-01-07 | Olin Mathieson | Benzothiazole, benzothiazine, and benzothiazepine compounds |
FR1255312A (fr) * | 1957-10-31 | 1961-03-10 | Crookes Lab Ltd | Dérivés des aryl-benzothiazoles et leur mode de préparation |
GB1058822A (en) * | 1963-07-30 | 1967-02-15 | Ici Ltd | 3-amino-2-hydroxypropoxy heterocyclic derivatives |
GB1047927A (en) * | 1964-03-09 | 1966-11-09 | Ici Ltd | Alkanolamine derivatives |
BE754245A (fr) * | 1969-08-01 | 1970-12-31 | Sumitomo Chemical Co | Derives d'acides phenoxy carboxyliques |
US3574218A (en) * | 1969-08-11 | 1971-04-06 | Egyt Gyogyszervegyeszeti Gyar | 2-aryl- or aralkyl-substituted benzazole derivatives |
US3720683A (en) * | 1970-09-02 | 1973-03-13 | Squibb & Sons Inc | 2-phenyl-3-acylbenzothiazolines and their oxides |
JPS5371071A (en) * | 1976-12-08 | 1978-06-24 | Teijin Ltd | Alpha-phenoxyacetic acid derivs. |
JPS57179175A (en) * | 1981-04-30 | 1982-11-04 | Shinzo Kano | Preparation of 2-benzothiazolinone derivative or salt thereof |
JPS5846079A (ja) * | 1981-09-12 | 1983-03-17 | Santen Pharmaceut Co Ltd | ベンゾチアゾリン環を有するエ−テル類 |
-
1981
- 1981-09-12 JP JP56144148A patent/JPS5846079A/ja active Pending
-
1982
- 1982-09-07 IT IT23146/82A patent/IT1196423B/it active
- 1982-09-10 AT AT0904882A patent/AT379592B/de not_active IP Right Cessation
- 1982-09-10 CA CA000411159A patent/CA1169860A/fr not_active Expired
- 1982-09-10 US US06/503,160 patent/US4479949A/en not_active Expired - Lifetime
- 1982-09-10 AU AU89026/82A patent/AU541223B2/en not_active Ceased
- 1982-09-10 NL NL8220310A patent/NL8220310A/nl not_active Application Discontinuation
- 1982-09-10 GB GB08311096A patent/GB2115815B/en not_active Expired
- 1982-09-10 CH CH2716/83A patent/CH654001A5/de not_active IP Right Cessation
- 1982-09-10 ES ES515655A patent/ES8308552A1/es not_active Expired
- 1982-09-10 BE BE2/59831A patent/BE894358A/fr not_active IP Right Cessation
- 1982-09-10 WO PCT/JP1982/000363 patent/WO1983000865A1/fr active IP Right Grant
- 1982-09-10 DE DE823248957T patent/DE3248957T1/de active Granted
- 1982-09-13 FR FR8215454A patent/FR2512820B1/fr not_active Expired
-
1983
- 1983-04-26 SE SE8302352A patent/SE444681B/sv not_active IP Right Cessation
- 1983-04-27 FI FI831431A patent/FI68232C/fi not_active IP Right Cessation
- 1983-05-10 NO NO831653A patent/NO831653L/no unknown
- 1983-05-11 DK DK211283A patent/DK164403C/da not_active IP Right Cessation
- 1983-05-13 ES ES522386A patent/ES8407033A1/es not_active Expired
-
1984
- 1984-05-21 US US06/612,323 patent/US4558125A/en not_active Expired - Fee Related
- 1984-05-21 US US06/612,322 patent/US4552969A/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI68232C (fi) | Foerfarande foer framstaellning av benzotiazolinfoereningar me farmaceutiskt verkan | |
ES2450081T3 (es) | Compuestos cíclicos condensados como moduladores del receptor GPR40 | |
FI91637B (fi) | Menetelmä valmistaa farmakologisesti vaikuttavia kinuklidiineja | |
FI98367C (fi) | Menetelmä uusien terapeuttisesti käyttökelpoisten trisyklisten, typpipitoisten yhdisteiden valmistamiseksi | |
Mellin et al. | A 3 dimensional model for 5-HT1A-receptor agonists based on stereoselective methyl-substituted and conformationally restricted analogs of 8-hydroxy-2-(dipropylamino) tetralin | |
PT97490A (pt) | Processo para a preparacao de derivados de isoquinolina | |
Bermudez et al. | 5-Hydroxytryptamine (5-HT3) receptor antagonists. 2. 1-Indolinecarboxamides | |
PT88438B (pt) | Processo para a preparacao de esteres e amidas azabiciclicos | |
FI81344B (fi) | Foerfarande foer framstaellning av nya farmakologiskt verksamma 2-fenyl-3-oxo-1,4-bensotiazinderivat. | |
FI71123C (fi) | Analogifoerfarande foer framstaellning av som laekemedel anvaendbar 2-/2'-hydroxi-3'-(1,1-dimetylpropylamino)- propoxi/-beta-fenylpropiofenon och syreadditionssalter av denna | |
PT90572B (pt) | Processo para a preparacao de derivados de 6-fenil-3-piperazinilalquil-1h,3h-2,4-pirimidinadiona | |
PT99831A (pt) | Processo para a preparacao de derivados de acido benzoico contendo uma cadeia lateral di-azaciclica ou azabiciclica | |
PT92609B (pt) | Processo para a preparacao de derivados 4,5,6,7-tetrahidroben zimidazoles | |
WO2003004501A2 (fr) | Composes therapeutiques | |
Froimowitz et al. | Further evidence for a dopamine reuptake pharmacophore. The effect of N-methylation on threo-methylphenidate and its analogs | |
DK166275B (da) | Derivater af phenyl, pyrrolidin-2-yl substitueret pyrrol og farmaceutisk acceptable syreadditionssalte heraf med antipsykotiske egenskaber, fremgangsmaade til fremstilling heraf, samt farmaceutiske praeparater indeholdende disse forbindelser | |
JP4593879B2 (ja) | ニコチン性アセチルコリンレセプターリガンドおよび/またはセロトニン作動性リガンドとしてのジヒドロイミダゾ[4,5−e]インドールおよび7H−ピロロ[3,2−f]キノキサリン誘導体 | |
PT99771A (pt) | Processo para a preparacao de derivados de benzodioxole | |
ES2218930T3 (es) | Nuevos derivados basicos de benzo(e)isoindol-1-onas y pirrolo(3,4-c)quinolin-1-onas con actividas antagonista de 5-ht3, su preparacion y su uso terapeutico. | |
US7291738B2 (en) | Therapeutic compounds | |
SK14482003A3 (sk) | Deriváty 6H-oxazolo[4,5-e]indolu ako ligandy nikotínacetyl- cholínového receptora a/alebo serotonergické ligandy, spôsob ich prípravy a ich použitie | |
NZ318434A (en) | Naphthamide derivatives of 3 beta-amino azabicyclo octane or nonane as neuroleptic or antipsychotic agents | |
Abdel-Fattah et al. | D 1-like receptors distinguishing thieno-azecine regioisomers | |
CA3118738A1 (fr) | Inhibiteurs de kinases rock | |
JP2022055368A (ja) | ベンゾアゼピン誘導体の製造方法及びその中間体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM | Patent lapsed | ||
MM | Patent lapsed |
Owner name: SANTEN PHARMACEUTICAL CO., LTD |